TNFSF15 and neoplasm: To maintain a bivalent interaction with the tumor antigen of choice, we chose to replace the C-terminal scFv antibody in homodimeric tetravalent BiMAb by the ectodomain of either 4-1BBL, OX40L, TL1A or CD70.